

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Biosysen

The Bioware Company

BIOSYSEN LIMITED

生物系統工程有限公司

*(formerly known as “Legend Strategy International Holdings Group Company Limited
枋濬國際集團控股有限公司”)*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1355)

APPOINTMENT OF INDEPENDENT FINANCIAL ADVISER

Reference is made to the announcement of Biosysen Limited (the “**Company**”) dated 26 May 2026 in relation to, among others, the connection transaction in relation to the proposed issue of the Convertible Bonds under the Specific Mandate (the “**Announcement**”). Unless the context requires otherwise, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

The Board wishes to announce that, with the approval of the Independent Board Committee, Gram Capital Limited, being a licensed corporation to carry out Type 6 (advising on corporate finance) regulated activity under the SFO, has been appointed as the Independent Financial Adviser to advise the Independent Board Committee and the Independent Shareholders in relation to the Subscription and Settlement Agreement and the transactions contemplated thereunder (including the grant of the Specific Mandate).

Completion of the Subscription is subject to the fulfilment or waiver (as applicable) of the conditions precedent set out in the Subscription and Settlement Agreement. Accordingly, the Subscription may or may not proceed. Shareholders and potential investors of the Company should exercise extreme caution when dealing in the Shares.

By order of the Board
Biosysen Limited
Lee Tsz Yan
Executive Director

Hong Kong, 1 June 2026

As at the date of this announcement, the Board comprises Ms. Lee Tsz Yan as executive Director; Mr. Cheung Ching Mo and Mr. Hu Xinglong as non-executive Directors; and Mr. Wu Jilin, Mr. Lam Cheung Shing Richard and Mr. So Yin Wai as independent non-executive Directors.